XML 40 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting
6 Months Ended
Dec. 31, 2021
Segment Reporting  
Segment Reporting

18. Segment reporting

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Aytu BioPharma and Aytu Consumer Health. The Aytu BioPharma segment consists of the Company’s prescription products. The Aytu Consumer Health segment contains the Company’s consumer healthcare products.

Select financial information for these segments is as follows:

Three Months Ended

Six Months Ended

December 31, 

December 31, 

    

2021

    

2020

2021

    

2020

(In thousands)

(In thousands)

Consolidated revenue:

  

 

  

  

 

  

Aytu BioPharma

$

14,643

$

7,212

$

28,526

$

12,964

Aytu Consumer Health

 

8,482

 

7,935

 

16,496

 

15,703

Consolidated revenue

$

23,125

$

15,147

$

45,022

$

28,667

Consolidated net loss:

 

  

 

  

 

  

 

  

Aytu BioPharma

$

(9,591)

$

(8,268)

$

(36,048)

$

(11,218)

Aytu Consumer Health

 

(1,957)

 

(1,257)

 

(3,351)

 

(2,613)

Consolidated net loss

$

(11,548)

$

(9,525)

$

(39,399)

$

(13,831)

December 31, 

June 30, 

2021

2021

(In thousands)

Total assets:

Aytu BioPharma

$

194,419

$

236,449

Aytu Consumer Health

 

29,405

 

29,219

Consolidated assets

$

223,824

$

265,668